+357 96 030922
info@marketpublishers.com

Biologics Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Recombinant Proteins & Enzymes), By Service, By Source, By Workflow, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2026 - 2033

https://marketpublishers.com/r/B58266195329EN.html
Date: April 2026
Pages: 120
Price: US$ 5,950.00 (Single User License)
ID: B58266195329EN

Abstracts

The global biologics contract development and manufacturing organization market size was estimated at USD 47.84 billion in 2025 and is projected to reach USD 84.91 billion by 2033, growing at a CAGR of 7.4% from 2026 to 2033. The market is driven by the rising prevalence of chronic and rare diseases, an aging global population, and the growing demand for highly targeted therapies.

Besides, increasing biosimilar adoption provides cost-effective alternatives while expanding patient access. In addition, some other factors contributing to market growth are rising leadership teams that align network strategies with long-term therapeutic pipelines, next-generation manufacturing technologies, scientific breakthroughs, regulatory shifts, supply chain disruptions, and shifting patient demographics. Thus, these factors are creating a robust demand for the biologics pipeline in the pharmaceutical industry.

Moreover, most pharmaceutical & biopharmaceutical companies are increasingly partnering with CDMO service providers to expand capacity and access specialized technologies, while private equity and institutional investors are expanding their funds into platform companies with innovative models. Furthermore, growing investments in biologics are expected to drive venture capital, strategic collaborations, mergers, and acquisitions, further contributing to market growth across the value chain. Most

+357 96 030922
info@marketpublishers.com

pharmaceutical & biopharmaceutical companies are increasingly partnering with CDMO service providers to expand capacity and access specialized technologies.

According to the data published by Fierce Pharma in June 2025, several CDMOs are announcing significant expansions to meet rising biologics outsourcing demand: WuXi Biologics recently announced the opening of a new 95,000 m? facility in China that likely to feature a 15,000-liter fermenter and annual output exceeding 10 million vials once operational, while Aragen is preparing to begin GMP biologics manufacturing at its Bangalore facility with high-productivity fed-batch platforms later this year. These expansion initiatives highlight how capacity scaling and long-term manufacturing deals directly respond to the complex production needs of biologics developers across regions.

In addition, technological advancements are reshaping the development of medications, including biologics with complex modalities such as bispecific antibodies, antibody-drug conjugates, CAR-T therapies, and mRNA-based treatments, further fueling strategic investments and drug innovation. Besides, there is a growing breakthrough in bioprocessing, including the use of single-use bioreactors, continuous manufacturing, and advanced process modeling, which have significantly improved efficiency & scalability. Moreover, growing integration of digitalization, automation, and artificial intelligence into drug discovery, development, and manufacturing processes further enables faster timelines and increased product success rates. Thus, these innovations enhance therapeutic precision and boost new growth opportunities for personalized and small-batch production to meet niche patient needs.

In addition, most large pharmaceutical companies are focusing on acquisitions to strengthen their biologics pipelines, diversify therapeutic portfolios, and secure advanced manufacturing capabilities. Thus, these capital investments and strategic innovations are accelerating commercialization and reshaping the competitive landscape, and are expected to drive the market over the estimated period.

In addition, amid growing regulatory scrutiny, the U.S. FDA, EMA, and other global authorities are refining approval pathways for cell therapies, biosimilars, and gene-based treatments, issuing guidelines to encourage innovation while safeguarding patient safety. Besides, harmonized standards across regions support streamlining submissions and reducing delays, while post-market surveillance & evidence requirements remain stringent in the market. The evolving regulatory environment enables faster approvals for novel therapies while increasing the compliance burden on developers to meet rigorous chemistry, manufacturing, and control requirements. Such

+357 96 030922
info@marketpublishers.com

factors are expected to drive the market over the estimated time period.

Global Biologics Contract Development And Manufacturing Organization Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biologics contract development and manufacturing organization market report based on product, service, source, workflow, therapeutic area, end use, and region.

Product Outlook (Revenue, USD Million, 2021 - 2033)

Monoclonal antibodies (mAbs)

Recombinant proteins & enzymes

Vaccines

Cell & Gene Therapies

Nucleic acid Therapeutics

Others

Service Outlook (Revenue, USD Million, 2021 - 2033)

Contract Development

Cell Line Development

Process Development

Upstream

Downstream

Analytical Testing & Method Validation

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

Neurology

Others

End Use Outlook (Revenue, USD Million, 2021 - 2033)

Pharmaceutical Companies

Biotechnology Companies

Academic and Research Institutions

Others

Regional Outlook (Revenue, USD Million, 2021 - 2033)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Denmark

+357 96 030922
info@marketpublishers.com

- Sweden
- Norway

Asia Pacific

- Japan
- China
- India
- Australia
- Thailand
- South Korea

Latin America

- Brazil
- Argentina

Middle East & Africa

- South Africa
- UAE
- Saudi Arabia
- Kuwait
- Qatar
- Oman

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 4. BIOLOGICS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

+357 96 030922
info@marketpublishers.com

CHAPTER 5. BIOLOGICS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: SERVICE ESTIMATES & TREND ANALYSIS

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 8. BIOLOGICS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS

CHAPTER 9. BIOLOGICS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: END USE ESTIMATES & TREND ANALYSIS

+357 96 030922
info@marketpublishers.com

CHAPTER 10. BIOLOGICS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 11. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Biologics Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Recombinant Proteins & Enzymes), By Service, By Source, By Workflow, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2026 - 2033

Product link: https://marketpublishers.com/r/B58266195329EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/B58266195329EN.html